ABSTRACT We have used the expression of the muscle form of creatine phosphokinase (M-CPK) to assay myogenic differentiation in the cloned muscle cell line BC3HI. BC3HI cells express M-CPK when arrested in the Go portion of the cell cycle. Addition of the anionic form of brain fibroblast growth factor (B-FGF) rapidly represses synthesis of M-CPK with a half-time of 7 h. Even though B-FGF is not mitogenic for the cells, it causes quiescent BC3HI cells to exit from the Go portion of the cell cycle, and to accumulate at a new restriction point ~4 to 6 h in the G1 portion of the cell cycle. The repression of M-CPK synthesis by B-FGF is reversible upon removal of B-FGF, and cells which have re-initiated expression of M-CPK have also returned to the Go portion of the cell cycle. The primary control of M-CPK expression by B-FGF appears to be at the level of gene transcription. We conclude that arrest of cells at Go but not at other positions in the Gt phase of the cell cycle provides permissive conditions for the expression of muscle-specific proteins, and that defined polypeptide growth factors, in this case B-FGF, are important in the control of the expression of muscle-specific proteins.
The process of muscle differentiation requires the coordinated expression (induction) of a group of proteins associated with the muscle phenotype (1) (2) (3) . The induction of muscle-specific proteins occurs after myoblasts cease proliferation, and are arrested early in the G~ portion of the cell cycle (4, 5) .
A number of permanent cell lines can be induced to express proteins associated with the muscle phenotype (for review see reference l). Some of these cell lines, which do not fuse to form multinucleated myotubes, also do not become irreversibly committed to the differentiated phenotype. Upon addition of mitogens, usually serum, these cells reinitiate growth and concomitantly the expression of muscle-specific proteins is repressed (5-7). We have used BC3H1 cells, a clonal muscle cell line, to examine the control of cell differentiation by mitogenic polypeptides using the muscle form of creatine phosphokinase (M-CPK) ~ as a probe to assay cell differentiation. We have reported recently that addition to differentiated BC3H1 cells of serum, commercial (impure) pituitary fibroAbbreviations used in this paper: B-CPK and M-CPK, the brain and muscle forms of creatine phosphokinase; B-FGF, the anionic form of brain fibroblast growth factor. 2194 blast growth factor, or pure anionic brain fibroblast growth factor (B-FGF) results in repression of M-CPK synthesis (7, 8) . Under the conditions used, B-FGF is nonmitogenic for BC3HI cells, suggesting that it is possible to dissociate the mitogenic response from the repression of muscle-specific protein synthesis. Observations have recently been reported in preliminary form showing that cell growth is not required for repression of muscle-specific functions (9) .
In this communication we examine in detail the repression of M-CPK by addition of B-FGF to differentiated BCaHI cells. We demonstrate that B-FGF causes quiescent BC3H1 cells to exit from Go into Gl and become arrested at a new restriction point within Gt. The repression of M-CPK synthesis appears to be concomitant with, or follow shortly after, the exit of BC3HI cells from Go, and apparently reflects a rapid decline in the rate of transcription of the M-CPK gene.
by re-feeding with DME supplemented with 1% serum. Unless otherwise indicated, B-FGF (5 ng/ml) was added to quiescent differentiated BC3HI cells in a simplified medium of DME and F l2 at a 3:1 ratio supplemented with 250 #g/ml bovine serum albumin (BSA), 50 ~g/ml transferrin, 0.25% serum, and antibiotics as described (8) .
Determination of Rate of CPK Synthesis:
The rate of CPK synthesis was determined by immunoprecipitation of Triton X-100-solubilized extracts that had been pulse labeled for 2 h with 100 #Ci/ml [35S]mcthionine as described (8) . M-and B-isozymes of CPK were separated by SDS PAGE, and the radioactive bands were visualized by fluorography. The relative rate of synthesis of M-CPK was determined by densitometry of fluorographs (8) .
Ornithine Decarboxylase Assay: Ornithine decarboxylase was assayed by the release of radioactive CO2 from L-ornithine essentially by the method of Heller et al. (I l) . Cell monolayers were washed twice with cold phosphate-buffered saline and harvested by scraping in l0 mM Tris-HC1, pH 7.2, 50 mM KCI, 0.1 mM EDTA, 0.05 mM pyridoxal phosphate, 5 mM dithiothreitol, and 0.025% Tween 20 at 4°C. Reactions were carried out in stoppered 12-ml glass conical centrifuge tubes at 37*(? for 1 h. 150 ~1 of extract were added to 15 ul L-l-[~4C]ornithine (Amersham Corp., Arlington Heights, IL) (8 x 10 -s M) at a final specific radioactivity of 7.5 Ci/mol, and 10 ul of 0.5 M Tris-HC1, pH 7.2. Reactions were quenched by injecting 0.2 ml of 10% trichtoroacetic acid through the stopper, and liberated radioactive CO2 was trapped with a wick soaked with 100 ul of 10% NaOH held in place by a center well (Kontes Co., Vineland, N J). Wells with wicks were counted in 10 ml 3a70 scintillation fluid (Research Products International Corp., Mt. Prospect, IL). The assay was linear with respect to extract concentration and time.
Other Procedures: Fixing, mounting and developing cultures for autoradiography after labeling with [aH]thymidine was carried out essentially by the method of Cassel et al. (12) . Cultures were grown on 35-mm dishes, and after labeling with [3H]thymidine, the cultures were washed once with 2 ml of phosphate-buffered saline, and fixed overnight with 2 ml of 4% paraformaldehyde in the same buffer. The rim of the dishes was removed and the bottom processed for autoradiography (12) . I uCi/ml of [3H]methylthymidine (6.7 Ci/ mmol; New England Nuclear, Boston, MA) was used for 48-h labeling of BC3HI cultures. For 15-h cumulative labeling experiments, 3 uCi/ml were used.
The rate of thymidine incorporation was measured by trichloroacetic acidprecipitable radioactivity incorporated after a l-h pulse with 3 uCi/ml of [3H] thymidine (6.7 Ci/mmol), as described by Whittenberger and Glaser (13) . Uridine incorporation was measured by the same procedure after cultures had been pulsed with 2 ~Ci/ml of [~H]uridine (30 Ci/mmol; New England Nuclear) for 1 h. Labeling was linear with respect to time at these concentrations of isotopes. Epidermal growth factor was prepared as described (14) .
RESULTS
When BC3HI cells are cultured in 1% serum, they cease to proliferate and synthesize muscle-specific proteins such as M-CPK. Fig. 1 shows that addition of B -F G F to differentiated cells, as described in Materials and Methods, results in a rapid decline of the rate of M -C P K synthesis as measured by immunoprecipitation from cells labeled with [3SS]methionine for 2 h. A half-life o f 7 h for the decline in the rate o f M -C P K synthesis can be estimated from the data in Fig. l , and within the resolution of the method the decline is initiated without a significant time lag.
The decline in the rate of M -C P K synthesis observed in Fig. 2 ). B-FGF does not alter the rate of total protein synthesis in these cultures, and in some instances increases total rate of protein synthesis by 20% (not shown). The B and M isozymes of CPK in A are indicated by arrows. 0.2 ug/ml. The former level decreased the rate of uridine incorporation into R N A by 89% and the latter by 97%. U n d e r the same conditions, the rate o f synthesis o f a number o f major cellular polypeptides detected by one-dimensional gel electrophoresis was reduced by <25%, indicating that actinomycin-D does not significantly block protein synthesis nonspecifically under these conditions. While these observations will have to be confirmed by direct measurements of the cellular level of M -C P K m R N A , they strongly suggest that the major effect of B-FGF is at the level of gene transcription. 
BC3HI Cells in the Presence of B-FGF Transit from G0 to GI
Previous observations (8) have indicated that, under our culture conditions, B-FGF was not mitogenic for BC3HI ceils as determined by cell number 48 h after addition of B-FGF to cells. We have, in addition, used various combinations of B-FGF with insulin (1 ~g/ml), epidermal growth factor (10 ng/ml), dexamethasone (0.5 t~g/ml), and phorbolmyristic acid (100 ng/ml), and failed to observe an increase in cell number due to B-FGF after addition to quiescent BC3HI cells. cycle, does it nevertheless move cells from Go to G:? When quiescent BC3H1 cells are stimulated with serum, they enter S-phase after ~12 h (Fig. 3) . If B-FGF causes BCsHI cells to move into G,, then when serum is added to BC3H1 cells pretreated with B-FGF, the time required for these cells to enter S-phase should be shortened. Fig. 3 illustrates that this is in fact observed; pretreatment of BC3H1 cells for either 4 or 12 h with B-FGF before addition of 20% serum decreases the time required to enter S-phase from 12 h to 7 or 8 h, consistent with B-FGF permitting the movement of BCsH1 cells ~4 h into Gt. Since a 4-h pretreatment with B-FGF almost maximally reduces the duration of G: (Fig. 3) , B-FGF must move cells rapidly out of Go. The same observations have been obtained in three independent experiments. The time dependence of the movement of cells out of Go is consistent with time required to initiate repression of M-CPK synthesis.
There is a potential ambiguity in measuring the rate of entry of cells into S-phase by the use of acid-precipitable thymidine which may not correlate precisely with the number of cells entering S-phase. We have repeated the experiment in Fig. 3 by measuring the number of cells entering S-phase by autoradiography following labeling of cells with [3H]thymidine to determine directly the number of cells entering Sphase. The results in Fig. 4 confirm the data in Fig. 3 and clearly indicate that B-FGF addition to quiescent BC3H1 cells brings these cells 3-4 h into GI.
An independent measure of entry of cells into G~ is the induction of ornithine decarboxylase (15) . In Fig. 5 we show that addition of B-FGF to quiescent BC3HI cells causes a small but reproducible increase in ornithine decarboxylase, fully consistent with the entry of these cells into G~, and arrest at a new restriction point -4 -6 h into GI, at which point induction of ornithine decarboxylase is possible. The obser- vation that ornithine decarboxylase is activated by B-FGF indicates that this growth factor activates at least some of the ordered series of events that occur when cells are stimulated to transit G~ (16, 17) . Because various components in serum may also influence the induction of ornithine decarboxylase, we do not believe that the absolute level of ornithine decarboxylase after the addition of B-FGF to quiescent cells can be compared in a meaningful way with the level observed after addition of serum.
Is the Repression of M-CPK Synthesis by B-FGF Reversible?
Since B-FGF causes BC3HI cells to arrest within O~, and simultaneously represses M-CPK synthesis, is this repression reversible, and is it reversible in the absence of progression through the cell cycle? To answer this question, quiescent BCaH1 cells, which synthesize M-CPK, were treated with B-FGF for 48 h. Control cells received fresh B-FGF at 24 h. 24 h after addition of B-FGF, the rate of M-CPK synthesis is depressed ( Fig. 6 ; compare lane 2 with lane 4). However, 48 h after addition of B-FGF (in the absence of daily addition of B-FGF), the rate of M-CPK synthesis has returned to the fully-induced level (compare lanes 3 and 5), indicating that the repression is reversible. The reinduction at 48 h most likely reflects the depletion of B-FGF from the medium, and We asked whether the cells under these conditions had returned to Go by measuring the time required for such cells to enter S-phase after stimulation by serum. The data in Fig.  ? are consistent with these cells having returned to Go. Cells which have re-entered the differentiation program after exposure to B-FGF are indistinguishable from cells never exposed to B-FGF when we measure the time required by these cells to enter S-phase after addition of 20% serum (Fig. 7) . Labeling of cells with [3H]thymidine during the 48-h reversal period, followed by autoradiography, indicates that only 13% of the cells traversed the S-phase either in the presence or absence of B-FGF and, therefore, that the majority of the cells returned to Go without traversing the cell cycle. It is known from other cells that commitment to proceed through the cell cycle is a late event in GI (16) . B-FGF-treated BC3HI cells are arrested early in G~, presumably before this commitment point is reached.
DISCUSSION
The original definition of Go was that of a restriction point early in Gt, at which normal cells arrested in the absence of mitogens (16) . Several observations suggest that Go represents a unique metabolic state of quiescent cells and that, during logarithmic growth, cells bypass Go and never enter this metabolic state (see, for example, references 16, 18, and 19). Our observations define the metabolic state of BCaH1 cells and, by inference, of other muscle cells as the state which is permissive for the expression of muscle-specific proteins.
The addition of polypeptide growth factors to quiescent BCaH1 cells initiates movement of the cells from Go to G~. Exit of the cells from Go appears to be closely associated with repression of the synthesis of M-CPK. Though our data suggest that B-FGF allows BC3H1 cells to progress rapidly into G~ (see Fig. 3 ), the repression of M-CPK synthesis seems to start immediately after addition of B-FGF so that, 3 h after addition of this growth factor, the rate of M-CPK synthesis is already decreased by 40%.
Although all the experiments reported here were carried out with B-FGF, we have recently carried out similar experiments with identical results with highly purified pituitary FGF prepared as described by Bohlen et al. (20) . Although these two polypeptide growth factors are distinct proteins, their metabolic effects on BC3H1 are very similar.
Differentiation of a few other cell lines has been examined carefully regarding the role of different compartments in the cell cycle in the differentiation process. For example, the conversion of 3T3 preadypocytes to adypocytes occurs in Go, but arrest of cells later in the cell cycle is nonpermissive for adypocyte differentiation (21, 22) .
We would suggest that the control by polypeptide growth factors of cell differentiation is not only relevant to established cell lines in culture, but may also be of importance in controlling the expression of muscle cell proteins in vivo, first in preventing differentiation during periods of active cell proliferation, but also in mature cells by controlling the expression of gene products characteristic of differentiated cells in the absence of cell division. Note that in BC3HI cells it is possible to go from a differentiated phenotype (high rate of synthesis of M-CPK) to a relatively undifferentiated state (low rate of synthesis of M-CPK) and back again to the differentiated state in the absence of cell division, and to do so without traversing the cell cycle by simply controlling the level of B-FGF in the culture medium. A critical test of the validity of this speculation will require an increased understanding of the role of B-FGF in the whole animal.
